New hope for tough bladder cancers: first human trial begins
NCT ID NCT06351904
Summary
This is an early-stage study testing a new drug called RAG-01 for people with a specific type of bladder cancer that has returned after standard BCG treatment. The main goals are to check if the drug is safe, see how the body processes it, and find the best dose for future testing. About 72 participants will receive the drug directly into the bladder to see if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare North Shore
RECRUITINGSt Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peninsula & South Eastern Haematology and Oncology Group
RECRUITINGMelbourne, Victoria, 3199, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Melbourne Hospital
RECRUITINGMelbourne, Victoria, 3050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.